Previous 10 | Next 10 |
Are These Premarket Gaining Penny Stocks Worth Watching? Finding the biggest premarket gaining penny stocks is a great way to start your watchlist. And while it isn’t nearly the only way to start a trading day right, it can be a useful tool to see where the momentum may be headed...
Sesen Bio (NASDAQ:SESN) and Eczacibasi Pharmaceuticals have entered into a licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in Turkey. The company’s BLA for Vicineum is ...
Sesen Bio to receive $1.5 million upfront and is eligible for additional regulatory and commercial milestone payments Sesen Bio is entitled to receive a 30% royalty on net sales in Turkey Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing tar...
Sesen Bio (SESN) has completed its commercial build phase in preparation for the anticipated launch of Vicineum, if approved, in U.S., and has advanced to the implementation phase that will focus on executing its commercial strategy for Vicineum.The Biologics License Application ((BLA)) for V...
Hiring of the US sales force is 97% complete and sales training has commenced 14 Key Opinion Leader (KOL) speakers have been identified and speaker training has commenced Two-pronged market access and reimbursement strategy has commenced Sesen Bio (Nasdaq...
China-based venture capital firm Qiming has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial regional focus on Greater China and Asia. Shanghai Junshi Bio formed an mRNA Joint Venture with Hang...
Peter K Honig, MD, MPH and Michael A.S. Jewett, MD, FRCSC, FACS have joined the Sesen Bio Board of Directors as the Company nears potential US approval of Vicineum™ in August 2021 Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fus...
Anticipated submission of product market application for Vicineum in China in 2022, with potential approval in 2023 Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and...
Sesen Bio (SESN) pops 3.7% premarket after announcing that it participated in a Late-Cycle Meeting with the FDA regarding its Biologics License Application ((BLA)) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. The Late-Cycle Meeting is held l...
No Advisory Committee meeting is planned at this time No confirmatory trial required at this time Company believes it remains on track for August 18 th target PDUFA date Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted ...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...